Cell Death and Disease (Sep 2022)

MIIP functions as a novel ligand for ITGB3 to inhibit angiogenesis and tumorigenesis of triple-negative breast cancer

  • Yujing Gao,
  • Yujie Fang,
  • Yongli Huang,
  • Rui Ma,
  • Xixi Chen,
  • Fang Wang,
  • Xiuying Pei,
  • Yuanqi Gao,
  • Xuehua Chen,
  • Xinrui Liu,
  • Jingxuan Shan,
  • Pu Li

DOI
https://doi.org/10.1038/s41419-022-05255-0
Journal volume & issue
Vol. 13, no. 9
pp. 1 – 14

Abstract

Read online

Abstract Migration and invasion inhibitory protein (MIIP) has been identified as a tumor suppressor in various cancer types. Although MIIP is reported to exert tumor suppressive functions by repressing proliferation and metastasis of cancer cells, the detailed mechanism is poorly understood. In the present study, we found MIIP is a favorable indicator of prognosis in triple-negative breast cancer. MIIP could inhibit tumor angiogenesis, proliferation, and metastasis of triple-negative breast cancer cells in vivo and in vitro. Mechanistically, MIIP directly interacted with ITGB3 and suppressed its downstream signaling. As a result, β-catenin was reduced due to elevated ubiquitin-mediated degradation, leading to downregulated VEGFA production and epithelial mesenchymal transition. More importantly, we found RGD motif is essential for MIIP binding with ITGB3 and executing efficient tumor-suppressing effect. Our findings unravel a novel mechanism by which MIIP suppresses tumorigenesis in triple-negative breast cancer, and MIIP is thus a promising molecular biomarker or therapeutic target for the disease.